Bailey Whittington Pollock, PA-C | |
4220 N Rodney Parham Rd Ste 320, Little Rock, AR 72212-2466 | |
(501) 246-1042 | |
(501) 217-3809 |
Full Name | Bailey Whittington Pollock |
---|---|
Gender | Female |
Speciality | Physician Assistant - Medical |
Location | 4220 N Rodney Parham Rd Ste 320, Little Rock, Arkansas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437871571 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 1177669 (Arkansas) | Secondary |
363AM0700X | Physician Assistant - Medical | PA-1110 (Arkansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Bailey Whittington Pollock, PA-C 4220 N Rodney Parham Rd Ste 320, Little Rock, AR 72212-2466 Ph: (501) 246-1042 | Bailey Whittington Pollock, PA-C 4220 N Rodney Parham Rd Ste 320, Little Rock, AR 72212-2466 Ph: (501) 246-1042 |
News Archive
Officials from the National Institutes of Health and the city of Washington, D.C. today announced the new D.C. Partnership for HIV/AIDS Progress, a collaborative research initiative between NIH and the D.C. Department of Health designed to decrease the rate of new HIV infections in the city, improve the health of district residents living with HIV infection, and strengthen the city's response to the HIV/AIDS epidemic.
Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin.
Watson Pharmaceuticals, Inc. today confirmed that Watson has launched an authorized generic version of PROMETRIUM (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 4 days ago